Follow up
| Recurrence (%) | |
| No | 990 (85.6) |
| Yes | 126 (10.9) |
| Not reported | 40 (3.5) |
| Time to relapse, months (SD) | |
| Mean | 22.94 (17.32) |
| Median | 19 |
| Type of recurrence (%) | |
| Local (vagina, parametrial area, and pelvic retroperitoneum) | 69 (54.8) |
| Distant metastases (any other location) | 34 (27.0) |
| Both local and distant | 16 (12.7) |
| Not reported | 7 (5.6) |
| Time of follow-up, months (SD) | |
| Mean | 53.35 |
| Median | 58 |
| Status at last follow-up (%) | |
| Alive with disease | 37 (3.2) |
| Alive without disease | 1019 (88.1) |
| Death with disease | 53 (4.6) |
| Death without disease | 12 (1.0) |
| Lost to follow-up | 35 (3.0) |
| Disease-free survival at 5 years (%) | 88.3 |
| Overall survival at 5 years (%) | 94.9 |
| Overall survival at 3 years after relapse (%) | 51.7 |
| Overall survival at 5 years after relapse (%) | 40.7 |
| Median survival after relapse, months | 33.8 |
| Median follow-up after relapse, months | 19.6 |